DrugPatentWatch Archives
Click here to return to the current data set
|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and more than 2,300 generic ingredients from more than 1,700 branded and generic pharmaceutical companies, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Search for Tradename: OXYCONTIN
Summary for Tradename: OXYCONTIN
|
| |||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Exclusivity Expiration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Purdue Pharma Lp | OXYCONTIN | oxycodone hydrochloride | TABLET, EXTENDED RELEASE; ORAL | 020553 | Dec 12, 1995 | RX | No | 4,861,598 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Purdue Pharma Lp | OXYCONTIN | oxycodone hydrochloride | TABLET, EXTENDED RELEASE; ORAL | 020553 | Dec 12, 1995 | RX | No | 4,970,075 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Purdue Pharma Lp | OXYCONTIN | oxycodone hydrochloride | TABLET, EXTENDED RELEASE; ORAL | 020553 | Dec 12, 1995 | RX | No | 5,266,331 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Paragraph IV activity for: OXYCONTIN
| Drugname | Dosage | Strength | RLD | Submissiondate |
| oxycodone hydrochloride | Extended-release Tablet | 15 mg | OxyContin (NDA 022272) | 10/28/2010 |
| oxycodone hydrochloride | Extended-release Tablet | 40 mg | OxyContin (NDA 022272) | 10/4/2010 |
| oxycodone hydrochloride | Extended-release Tablet | 10 mg | OxyContin (NDA 022272) | 10/25/2010 |
| oxycodone hydrochloride | Extended-release Tablet | 30 mg, 60 mg and 80 mg | OxyContin (NDA 022272) | 10/18/2010 |
| oxycodone hydrochloride | Extended-release Tablet | 20 mg | OxyContin (NDA 022272) | 10/29/2010 |
| oxycodone hydrochloride | Extended-release Tablets | 15 mg | Oxycontin | 2/15/2007 |
| oxycodone hydrochloride | Extended-release Tablets | 30 mg and 60 mg | Oxycontin | 1/3/2007 |
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc